VIRGINIA BEACH, Va. (CN) – A man claims Amgen’s arthritis drug Enbrel gave him cancer, and that Amgen and its affiliates hid the extent of the drug’s side effects from doctors and their patients.

The needle stays hidden during injection and a sensor can detect placement on skin. It also includes 3 difference injection speeds, a progress bar and a speaker. Amgen announced the availability of ...

Whether starting or maintaining treatment, the Embark App has multiple features that can help patients on ENBREL throughout their treatment experience. As the healthcare industry continues to evolve ...

SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...

Americans with psoriasis and rheumatoid arthritis will have to wait much longer for low-priced copycat versions of their weekly Enbrel injections. Amgen (NASDAQ: AMGN) won an appeals court ruling on ...

THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel ® ...

The safety of etanercept in this patient population was established through multiple pediatric trials, including a clinical study in 69 children aged 2 to 17 years with moderately to severely active ...

Image source: Amgen via Flickr. Amgen (NASDAQ: AMGN), the original biotech blue-chip company, reported its third-quarter earnings results after the closing bell on Thursday, handily surpassing Wall ...

May 23, 2005 — The European Commission has approved a 50-mg/mL formulation of etanercept injection for the treatment of rheumatoid arthritis, and the U.K.'s Medicine and Healthcare Products Regulatory ...

Never fear, makers of anti-TNF giants: Those pesky biosimilars? They won’t be halting revenue growth anytime soon, Leerink Partners analysts predict. Taking into account current trends in prescription ...

THOUSAND OAKS, Calif., November 12, 2006 -- Amgen (NASDAQ: AMGN) today announced that Enbrel? (etanercept) is the first biologic with published data to show improvements in multiple measures of ...

An appeals court ruling means biosimilar competition won't affect U.S. Enbrel sales for a long time. Enbrel is a tumor necrosis factor (TNF) inhibitor that earned its first FDA approval all the way ...